Table 2.
Univariate and multivariate analyses of association between clinical parameters and overall survival.
| Clinical features | Patient numbers | Univariate | Multivariate | ||
| HR† (95% CI‡) |
P-value | HR† (95% CI‡) |
P-value | ||
|
| |||||
| Stage (I vs II vs III) | 13 : 27 : 65 | - | 0.001 ∗ | 1.907 (1.147-3.171) |
0.013 ∗ |
|
| |||||
| Tumor site (Upper vs Middle vs Lower) | 28 : 48 : 29 | - | 0.905 | - | - |
|
| |||||
| Gender (Male vs Female) | 98 : 7 | 0.737 (0.248-2.009) |
0.513 | - | - |
|
| |||||
| Age (≥ vs <60 years old) | 40 : 65 | 0.726 (0.399-1.260) |
0.241 | - | - |
|
| |||||
| Surgery (Yes vs No) | 38 : 67 | 2.046 (1.154-3.334) |
0.013 ∗ | 0.353 (0.182-0.687) |
0.002 ∗ |
|
| |||||
| Radiotherapy (4000~5000cGy vs >5000cGy) | 40 : 65 | 0.7847 (0.462-1.344) |
0.381 | - | - |
|
| |||||
| Days from diagnosis to initial treatment (< v.s ≥29) | 57 : 48 | 0.989 (0.583-1.677) |
0.966 | - | - |
|
| |||||
| Days from diagnosis to complete treatment (< v.s ≥69) | 54 : 51 | 0.704 (0.405-1.185) |
0.180 | - | - |
|
| |||||
| Hematologic Markers | |||||
|
| |||||
| Platelet count of pre-treatment (≥ vs <300,000/μL) | 34 : 71 | 0.535 (0.277-0.887) |
0.018 ∗ | 1.543 (0.778-3.061) |
0.217 |
|
| |||||
| Platelet count of post-treatment (≥ vs <300,000/μL) | 9 : 96 | 0.389 (0.078-0.704) |
0.010 ∗ | 2.656 (1.047-6.735) |
0.041 ∗ |
|
| |||||
| MPV§ (≥ vs <9.8fl) | 51 : 50& | 1.286 (0.750-2.207) |
0.361 | - | - |
|
| |||||
| Hemoglobin (≥ vs <14g/dL) | 17 : 88 | 1.426 (0.745-2.583) |
0.302 | - | - |
|
| |||||
| White blood count (≥ vs <10,000/μL) | 12 : 93 | 0.715 (0.255-1.795) |
0.432 | - | - |
|
| |||||
| Absolute Neutrophil count (≥ vs <4483/μL) | 53 : 52 | 0.617 (0.362-1.041) |
0.070 | - | - |
|
| |||||
| Neutrophil percentage (≥ vs <73.4%) | 53 : 52 | 0.729 (0.431-1.232) |
0.238 | - | - |
|
| |||||
| Absolute Monocyte count (≥ vs <449/μL) | 53 : 52 | 0.756 (0.444-1.276) |
0.292 | - | - |
|
| |||||
| Monocyte percentage (≥ vs <7%) | 53 : 52 | 0.955 (0.564-1.615) |
0.861 | - | - |
|
| |||||
| Absolute lymphocyte counts (≥ vs <1042/μL) | 53 : 52 | 1.627 (0.969-2.823) |
0.065 | - | - |
|
| |||||
| Lymphocyte percentage (≥ vs <16%) | 53 : 52 | 1.997 (1.205-3.548) |
0.008 ∗ | 0.431 (0.131-1.419) |
0.168 |
|
| |||||
| Biomarker of Inflammation | |||||
|
| |||||
| Platelet to-ALC∧ ratio (≥ vs <236) | 53 : 52 | 0.632 (0.368-1.064) |
0.083 | - | - |
|
| |||||
| Platelet-to-Lymphocyte(%) ratio (≥ vs <14605) | 53 : 52 | 0.514 (0.316-0.911) |
0.021 ∗ | 0.542 (0.245-1.200) |
0.133 |
|
| |||||
| Neutrophil-to-Lymphocyte ratio (≥ vs <4.35) | 53 : 52 | 0.507 (0.290-0.847) |
0.010 ∗ | 0.804 (0.258-2.504) |
0.709 |
†HR, hazard ratio; ‡CI, confidence interval; §MPV, mean platelet volume; ∧ALC, absolute lymphocyte count; &no data of 4 patients.